Aqueous flare is a major risk factor for PVR redetachment

Article

Preoperative aqueous flare is a significant risk factor for proliferative vitreoretinopathy (PVR) redetachment in patients with rhegmatogenous retinal detachment.

Preoperative aqueous flare is a significant risk factor for proliferative vitreoretinopathy (PVR) redetachment in patients with rhegmatogenous retinal detachment, according to a paper published in Retina.

Dr Sabine Schröder et al., Department of Vitreo-Retinal Surgery and Institute of Medical Statistics, Informatics and Epidemiology, Center of Ophthalmology, University of Cologne, Germany, preoperatively measured the aqueous flare of 116 consecutive patients with retinal detachment.

A laser flare-cell meter was used to conduct aqueous flare measurements. The control group consisted of 74 healthy eyes of 41 healthy age-matched patients. Six month postoperatively, patients were re-evaluated to determine whether surgery should be repeated due to PVR redetachment.

Higher flare values were found in eyes with retinal detachment that had developed PVR redetachment, compared to eyes with uneventful retinal detachment. All eyes with PVR redetachment had a flare value of over 10.8 photon counts per millisecond. In eyes with flare values of over 15 photon counts per millisecond the chances of PVR redetachment was found to increase 16 times.

The breakdown of the blood-ocular barrier, as determined by aqueous flare, presented as a major PVR redetachment risk factor. It was also found that the laser flare-cell meter is a non-invasive, efficient and safe device that enables the prediction of preoperative PVR redetachment risk.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.